Back

Effects of low-dose dapagliflozin on heart failure–related outcomes in patients with heart failure and type 2 diabetes: a subanalysis of the dapper study

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: New analyses and usage of old drugs Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Shin Ito

National Cerebral and Cardiovascular Center Hospital, Osaka (Japan)

5 More presentations in this session

Presentation thumbnail
Effect of empagliflozin on adenosine triphosphate levels in vivo in patients with type 2 diabetes mellitus combined with heart failure
Miss U. Omurzakova (Bishkek, KG)
Abstract
Presentation thumbnail
Vericiguat and cardiovascular outcomes in heart failure revisited: a bayesian reanalysis of 12,877 patients
Mr P. Batista (BR)
Abstract
Presentation thumbnail
Ambulatory milrinone in advanced heart failure: a single-center comparison of continuous and intermittent infusion strategies
Doctor A. Rioux (Quebec, CA)
Abstract
Presentation thumbnail
Long‑acting efficacy of oral stabilized bivalent liposomal iron therapy on iron balance and quality of life in chronic heart failure: more than iron supplementation
Doctor E. Tagliamonte (Nocera Inferiore, IT)
Abstract
Presentation thumbnail
Short‑ and long‑term efficacy of oral stabilized bivalent liposomal iron versus intravenous ferric carboxymaltose in chronic heart failure patients: is there a difference?
Professor E. Tagliamonte (Nocera Inferiore, IT)
Abstract

Access the full session

Session thumbnail
New analyses and usage of old drugs

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure
27 August 2021
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Session
HOT LINE SESSION 4
27 August 2022
thumbnail
Congress Presentation
Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources